deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT01124539

Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma

A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma

Sponsor: Arno Therapeutics

Conditions GBM Glioblastoma Multiforme Gliosarcoma
Interventions AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
Updated 6 times since 2017 Last updated: Dec 8, 2014 Started: Dec 31, 2009 Primary completion: Sep 30, 2014 Completion: Feb 28, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on GBM and Glioblastoma Multiforme, this trial is ongoing. The trial is conducted by Arno Therapeutics and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotUnknown Status~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Unknown Status PHASE2

    First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Arno Therapeutics
Data source: Arno Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations